Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of GZR33 versus insulin degludec in type 2 diabetes inadequately controlled with oral antidiabetic drugs
CTR20261150Phase 3Active
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of GZR33 in type 2 diabetes mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals. Started Apr 2026; status: active.
02
Drugs
GZR33
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20261150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261150.